12:35 PM EDT, 05/02/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month target price to $18 from $19, 4.3x our 2025 EPS estimate. We raise our 2024 EPS estimate to $4.33 from $4.21 to reflect the Q1 beat. We lower our 2025 EPS view to $4.39 from $4.59. Q1 EPS of $1.22 versus $1.10 beat the S&P Capital IQ consensus view of $0.93 and our forecast of $1.10, mainly driven by slightly higher-than-anticipated top-line revenue and adjusted EBITDA margin (33.2%). Q1 revenues of $1.6B rose by 5% Y/Y, $62M above the consensus, driven by better-than-expected performance in Women's Health (+12% Y/Y, 26% of total sales) and continued strong growth in Biosimilars sales (+46% Y/Y, 10% of total sales), counterbalancing the limited revenue growth in the core Established Brands segment (+2% Y/Y, 62% of total sales). With the fully reiterated guidance for 2024, as well as our expectation for 3% Y/Y top-line growth this year and another 2% Y/Y growth in 2025, we see limited catalysts to drive the stock price and maintain our Hold recommendation.